We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Time-series Analysis: PROMs from 2009-10 to 2014-15
Actions that trial sponsors should consider to build resilience into clinical trial design
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
How to use a patient-reported outcomes and experiences study to evaluate your digital health product.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Results for the Vivaldi study for antibody and cellular immune responses to coronavirus (COVID-19) in approximately 340 care homes.
Examines the treatment of multi-drug resistant-TB patients within and outside the National Tuberculosis Control Program
How to use a micro-randomised trial to evaluate your digital health product.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).